With a median follow-up time of 39.6 months, median overall survival was 13.0, 12.7, and 16.3 months for arms 1, 2, and 3, respectively. During induction chemotherapy, grade 3/4 granulocytopenia ...

The primary goal of this open-label, multicenter, randomized phase III trial was to determine whether treatment with carboplatin plus the oral fluoropyrimidine derivative S-1 was noninferior versus ...

Female patient talking to doctor. There was no significant difference in event-free survival between the carboplatin-containing arms. Adding carboplatin to neoadjuvant paclitaxel significantly ...

Treatment with retifanlimab plus carboplatin-paclitaxel statistically significantly reduced the risk of progression or death by 37% compared with placebo plus carboplatin-paclitaxel. The Food and Drug ...

CHICAGO (Reuters) - Abraxis Bioscience Inc said its cancer drug Abraxane outperformed the generic drug Taxol in patients with non-small cell lung cancer, without requiring patients to take steroids or ...

Most cases of high-grade serous ovarian cancer are not diagnosed until the disease has reached an advanced stage. New research has uncovered immunological changes in some cases of high-grade serous ...